At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 58 enrolled
Drug / intervention
Ravulizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
In Brief
A Phase 3 clinical trial evaluating Ravulizumab for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder. Completed, enrolled 58 participants across 41 sites in 13 countries.
Detailed Summary
The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Canada, Denmark, France, Germany, Italy, Japan, Poland, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedDec 2019
Primary CompletionMar 2022
Study CompletionOct 2024
TodayJul 2026
First PostedDec 17, 2019
Enrollment StartDec 9, 2019
Primary CompletionMar 15, 2022
Study CompletionOct 31, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.5 years ago
Interventions
Ravulizumabbiological
Participants will receive a weight-based loading dose of ravulizumab via IV infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until end of the Long-Term Extension Period.